|
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Lilly; Pfizer |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Mitsubishi Tanabe Pharma (Inst); MSD (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Celgene; Daiichi Sankyo |
Speakers' Bureau - Celgene; Merck; Roche; Sirtex Medical |
Research Funding - Sanofi |
Travel, Accommodations, Expenses - Amgen; Bayer; Celgene; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Bayer |
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Bayer |
|
Isabelle Ollivier-Hourmand |
Honoraria - Abbvie; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Intercept Pharmaceuticals |
Speakers' Bureau - Bayer; Gilead Sciences |
Travel, Accommodations, Expenses - Abbvie; Bayer; Gilead Sciences; MSD |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
No Relationships to Disclose |